Emergent Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Emergent Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-528	Closed	-$376K	–	118
2024 Q4	$376K	Sell	528 -36	-6%	-$30.2K	0.27%	72
2024 Q3	$593K	Buy	564 +40	+8%	+$44.5K	0.44%	43
2024 Q2	$586K	Buy	524 +2	+0.4%	+$1.94K	0.47%	42
2024 Q1	$502K	Buy	+522	New	+$496K	0.43%	42

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Emergent Wealth Advisors's REGN Position: Q1 2025 in Review

Emergent Wealth Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 528 shares — an estimated $376K sold.

Emergent Wealth Advisors first reported a position in REGN in Q1 2024 and held it in 4 quarters. The position peaked at $593K in Q3 2024. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Emergent Wealth Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Emergent Wealth Advisors sold 528 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $376K.
Emergent Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2024 and held it in 4 quarters.
Emergent Wealth Advisors's Regeneron Pharmaceuticals position peaked at $593K in Q3 2024.
1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Emergent Wealth Advisors's 13F filing for Q1 2025, filed 31 Oct 2025.